-
Innovation Ranking
Innovation Ranking – ACI Worldwide Inc
ACI Worldwide Inc (ACI) offers real-time electronic payment and banking solutions. The company develops, markets, installs, and supports software products and services related to electronic payments. It offers services and solutions to bank, merchants, intermediaries, and billers globally, which utilizes third party digital payment processors, payment associations, switch interchanges, and wide range of automated teller machines (ATM), merchant point-of sale (POS) terminals, bank branches, mobile phones, tablets, corporations, and internet commerce sites. ACI provides its products and services to the...
-
Product Insights
ACI Worldwide Inc Partner Ecosystem Profile
GlobalData's new report titled "ACI Worldwide Inc Partner Ecosystem Profile " serves as a crucial resource for analyzing the partner landscape of ACI Worldwide Inc. It identifies the company's partners across various countries and regions, and tracks over 70 data fields including IT solution areas of interest, business fundamental data (such as revenue and employee bands), partner engagement signing country, focused verticals, and more.It is based on data and information gathered from a range of sources including company websites, press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACI-35030 in Tauopathies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACI-35030 in Tauopathies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACI-35030 in Tauopathies Drug Details: ACI-35.030 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Citarinostat in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Citarinostat in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Citarinostat in Melanoma Drug Details: Citarinostat (ACY-241) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACI-35030 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACI-35030 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACI-35030 in Alzheimer's Disease Drug Details: ACI-35.030 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewOrthocell Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Orthocell Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Orthocell Ltd (Orthocell) is a regenerative medicine company. The company develops and commercializes medical devices and cellular therapies for the treatment of human tendons, bone, nerve and cartilage defects. It offers CelGro, a collagen medical device for repair and regeneration of dental bones and soft tissues. Orthocell is also evaluating its products to treat nerve and tendon injuries. The company...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Distal Symmetric Polyneuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Distal Symmetric Polyneuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Distal Symmetric Polyneuropathy Drug Details: Ricolinostat (ACY-1215) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Diabetic Neuropathic Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Diabetic Neuropathic Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Diabetic Neuropathic Pain Drug Details: Ricolinostat (ACY-1215) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Relapsed Multiple Myeloma Drug Details: Ricolinostat (ACY-1215) is under...